Vertex Pharmaceuticals (VRTX 223) —As opposed to November, when a bevy of clinical updates, submissions and approvals were released, Vertex has been quiet on the news front in recent weeks. But that hasn't stopped the stock from chugging higher without pausing for breath! Similar to DXCM, we view VRTX has a liquid leader of the medical sector--it's not likely to go bananas, but it certainly has the look and feel of a name that, after a couple of years in the wilderness, institutional investors are piling into because of the rapid and reliable growth coming up over the next couple of years at least. As with most names that have had a big run, some sort of pullback, rest or shakeout is possible, but the odds strongly favor the first retreat offering a solid entry point—frankly, we'd like to average up if the opportunity presents itself. As for the here and now, we'll stay on Buy, but consider starting with a smaller-than-normal position if you don't own any. BUY.